10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
The USA’s Institute for Clinical and Economic Review (ICER) yesterday released a Draft Evidence Report assessing the clinical effectiveness and value of Spinraza (nusinersen) from Biogen and Zolgensma (onasemnogene abeparvovec), from Novartis and its subsidiary AveXis, for the treatment of spinal muscular atrophy (SMA). 21 December 2018
French biopharma company DBV Technologies announced after market close on Wednesday that, after discussions with the US Food and Drug Administration, its Biologics License Application (BLA 20 December 2018
The US Food and Drug Administration has granted Breakthrough Therapy Designation for the anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). 20 December 2018
Switzerland-based Roivant Sciences yesterday announced that it has entered into a collaboration with Daiichi Sankyo to facilitate the out-licensing of investigational medicines. 20 December 2018
In yet another licensing deal, Gilead Sciences has entered into a strategic collaboration with Scholar Rock Holding to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. 19 December 2018
Japan’s Chugai Pharmaceutical has announced positive results from the Phase III SAkuraStar Study of satralizumab, a candidate to treat neuromyelitis optica spectrum disorder (NMOSD). 19 December 2018
California-based Amgen and Swiss firm Molecular Partners have agreed terms for a collaboration and license deal related to MP0310 (FAP x 4-1BB). 19 December 2018
US biotech firm Semma Therapeutics today announced the appointments of: David Lebwohl as chief medical officer; David DiGiusto as chief technology officer; and Ann Darda as head of human resources. 19 December 2018
One of Russia’s largest pharma distributors has in-licensed trans-dermally delivered pDNA-based therapeutic HIV vaccine technology from Genetic Immunity, a clinical stage biotech company. 18 December 2018
Competition is tough in the new anti-calcitonin gene-related peptide (CGRP) class of migraine drugs, so Teva Pharmaceutical Industries will be pleased to present a large dose of data in support of its recently-approved entry into the space. 18 December 2018
US biotech firm Sophiris Bio has released mixed Phase IIb study results of topsalysin for localized prostate cancer, including top-line safety and biopsy results from the patients who received a second administration of study drug, which appeared to be safe and generally well-tolerated. 18 December 2018
Eli Lilly saw its shares close down 3.19% at $108.36 yesterday, despite releasing positive clinical trial results with its interleukin (IL)-17 inhibitor compared to the world’s best selling prescription drug Humira (adalimumab). 18 December 2018
Seattle-based Kineta Immuno-Oncology (KIO), a subsidiary of privately-held biotech firm Kineta Inc, has entered into a strategic research collaboration to develop RIG-I agonist immunotherapies for the treatment of cancer. 17 December 2018
Hong Kong’s Innovent Biologics, which has recently completed a $400 million-plus IPO, today said it had entered into a licensing deal for three clinical-stage compound for the Chinese market 17 December 2018
New Jersey’s Advaxis has suffered a near-40% blow to its share price after the firm revealed that Amgen was tearing up a half-billion dollar collaboration to develop ADX-NEO. 17 December 2018
The US Food and Drug Administration has approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. 17 December 2018